GUIDED THERAPEUTICS INC

Overview

Compare with iTonic Holdings Ltd, POSITRON CORP or Nexalin Technology, Inc., or pick any stock.

• TickerGTHP on OTC²
• IndustryElectromedical & Electrotherapeutic Apparatus²
• HeadquartersNorcross, United States²
• Incorporated inDE³
• Business address5835 Peachtree Corners East, Suite B, Peachtree Corners, Ga 30092³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI549300A0UBF5OC8O7M54²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 2313878²

See how the biggest companies compare on our leaderboards

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.⁴ From its latest annual report

Corporate structure

GUIDED THERAPEUTICS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What GUIDED THERAPEUTICS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Inventory

Properties, in its own words

Our corporate offices, which also comprise our administrative, research and development, marketing and production facilities, are located at 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092, where we lease approximately 12,835 square feet under a lease that expires in July 2031.

Item 2 of the 10-K filed Mar 31, 2026.⁴

Leadership

Who has led GUIDED THERAPEUTICS INC, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerGene S. Cartwright Feb 7, 2014 to Jul 17, 2015¹³
• Chief executive officerMark L. Faupel Jan 16, 2009 to Apr 9, 2013¹⁴
• Chief executive officerMark A. Samuels Mar 31, 2006 to May 1, 2007¹⁵
• PresidentGene S. Cartwright Jun 20, 2014 to Jul 17, 2015¹⁶
• PresidentMark L. Faupel May 1, 2007 to Apr 9, 2013¹⁷
• Chief financial officerMark L. Faupel Dec 28, 2010 to Dec 28, 2011¹⁸
• Chief financial officerMark A. Samuels Mar 31, 2006 to May 1, 2007¹⁵
• Chief operating officerMark L. Faupel May 1, 2007 to May 1, 2007¹⁷

Former names

• SPECTRX INCNov 12, 1997 to Feb 28, 2008³

Timeline

1. Mar 10, 20268-K Entered a material agreement; Unregistered sale of shares; Other events³⁴
2. Dec 23, 20248-K Entered a material agreement³⁵
3. Sep 27, 20248-K Entered a material agreement³⁶
4. Mar 9, 20238-K Executive or director change³⁷
5. Sep 15, 20228-K Entered a material agreement; Unregistered sale of shares; Other events³⁸
6. Jul 29, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed³⁹
7. Jan 7, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed⁴⁰
8. Feb 7, 2014New chief executive Gene S. Cartwright becomes CEO¹³
9. Jan 16, 2009New chief executive Mark L. Faupel becomes CEO¹⁴
10. Mar 31, 2006New chief executive Mark A. Samuels becomes CEO¹⁵
11. Oct 27, 1992Founded GUIDED THERAPEUTICS INC is founded²

Filings

89 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 7 major events, 47 insider forms, 6 large holders, 9 other. The latest 20:

1. Aug 13, 202610-Q EDGAR
2. May 15, 202610-Q EDGAR
3. May 5, 20264 EDGAR
4. Apr 7, 20264 EDGAR
5. Apr 7, 20264 EDGAR
6. Apr 7, 20264 EDGAR
7. Mar 31, 202610-K EDGAR
8. Mar 12, 20264 EDGAR
9. Mar 10, 20268-K EDGAR
10. Mar 4, 20264 EDGAR
11. Nov 13, 202510-Q EDGAR
12. Sep 5, 20254 EDGAR
13. Sep 5, 20254 EDGAR
14. Sep 5, 20254 EDGAR
15. Sep 5, 20254 EDGAR
16. Aug 14, 202510-Q EDGAR
17. Jun 13, 20254 EDGAR
18. Jun 12, 20254 EDGAR
19. Jun 12, 20254 EDGAR
20. May 23, 20254/A FORM 4 A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 15 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Auctus Fund Management LLCSCHEDULE 13G/A, 4 filings Oct 24, 2022 to Nov 14, 2024⁴¹
• Rosalind Advisors, Inc.SC 13G/A, 2 filings Jul 6, 2022 to Feb 20, 2024⁴²

SEC filer profile

How GUIDED THERAPEUTICS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARGUIDED THERAPEUTICS INC¹
• CIK0000924515
• Employer ID (EIN)58-2029543⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address5835 Peachtree Corners East, Suite B, Peachtree Corners, GA 30092¹
• Phone7702428723¹
• Shares outstanding96,537,349 as of Aug 7, 2026¹²
• Public float$10.5M as of Jun 30, 2025⁴
• AuditorUHY LLP, Sterling Heights, Michigan PCAOB ID 1195; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceFeb 27, 1997¹
• Filings1,160 in all: 4 (276), 8-K (258), 424B3 (127), 10-Q (80), SC 13G/A (29), NT 10-Q (26), SC 13G (25), 10-K (24)¹
  All 51 form types

  DEF 14A (24), UPLOAD (23), CORRESP (22), EFFECT (21), S-1/A (19), 3 (18), 8-K/A (16), S-1 (16), 4/A (15), PRE 14A (13), POS AM (12), SC 13D/A (11), 10-Q/A (9), 10QSB (9), NT 10-K (8), S-8 (6), SC 13D (6), 10-K/A (5), PRER14A (5), 424B4 (4), D (4), REGDEX (4), RW (4), S-3/A (4), SC TO-I/A (4), 10-K405 (3), 10KSB (3), 3/A (3), REGDEX/A (3), 10-K405/A (2), 10QSB/A (2), 8-A12G (2), ARS (2), S-2/A (2), S-3 (2), SC TO-I (2), 10KSB/A (1), DEFA14A (1), DEFS14A (1), PRES14A (1), S-2 (1), SB-2 (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 31, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Jul 6, 2021
  Latest 8-K (8-K) Mar 10, 2026

Risk factors and legal proceedings

The risks GUIDED THERAPEUTICS INC names in Item 1A of its 10-K filed Mar 31, 2026: 37 risks under these headings, as written.⁴

• We will be required to raise additional funds. There is no assurance that such funds can be raised on terms that we would find acceptable, on a timely basis, or at all.
• If we cannot obtain additional funds when needed, we will not be able to implement our business plan.
• We have a history of losses, and we expect losses to continue.
• Our ability to sell our products is controlled by government regulations, and we may not be able to obtain any necessary clearances or approvals.
• In foreign countries, including European countries, we are subject to government regulation, which could delay or prevent our ability to sell our products in those jurisdictions.
• Russia’s invasion of Ukraine, and sanctions brought by the United States and other countries against Russia, have caused disruptions in many business sectors outside of the medical sector and have resulted in significant market disruptions and increased volatility in the price of certain commodities, including oil and natural gas.
• Escalation of geopolitical conflicts in the Middle East could adversely affect our business, financial condition, and results of operations.
• Risks related to tariffs and international trade policies could adversely affect our business, financial condition, and results of operations.
• In the United States, our products would be subject to regulation by the U.S. FDA, which could prevent us from selling our products domestically.
• Even if we obtain clearance or approval to sell our products, we are subject to ongoing requirements and inspections that could lead to the restriction, suspension or revocation of our clearance.
• We depend on a limited number of distributors and any reduction, delay or cancellation of an order from these distributors or the loss of any of these distributors could cause our revenue to decline.
• To successfully market and sell our products internationally, we must address many issues with which we have limited experience.

Legal proceedings

Although we may, from time to time, be involved in various legal claims arising out of our operations in the normal course of business, we are not currently subject to any claims or actions that we believe would have a material adverse effect on our financial position or results of operations.

The opening of Item 3, Legal Proceedings.⁴